Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Details
- Category: Business
![BioNTech BioNTech](/images/logo/biontech.png)
Novartis invests in early technical development capabilities for next-generation biotherapeutics
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Xenpozyme™ (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations)
- Details
- Category: Sanofi
![Sanofi Sanofi](/images/logo/sanofi.png)
BioNTech's statement on patent infringement lawsuit filed by Moderna
- Details
- Category: Business
![BioNTech BioNTech](/images/logo/biontech.png)
Moderna sues Pfizer and BioNTech for infringing patents central to Modernas innovative mRNA technology platform
- Details
- Category: Business
![Moderna, Inc. Moderna, Inc.](/images/logo/moderna.png)
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
The spin-off aims to maximize shareholder value by creating the #1 European generics company(1) and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines.
More Pharma News ...
- Pfizer and BioNTech submit application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine
- Bayer supports demining in Ukraine with donation to non-profit "Fondation suisse de déminage"
- Pfizer announces positive top-line results from Phase 3 study of 20-valent pneumococcal conjugate vaccine in infants
- Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
- Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
- Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
- Bayer Consumer Health leaders propose new principles for science-led self-care